1122. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial.
作者: Michelle L O'Donoghue.;Ruchira Glaser.;Matthew A Cavender.;Philip E Aylward.;Marc P Bonaca.;Andrzej Budaj.;Richard Y Davies.;Mikael Dellborg.;Keith A A Fox.;Jorge Antonio T Gutierrez.;Christian Hamm.;Robert G Kiss.;František Kovar.;Julia F Kuder.;Kyung Ah Im.;John J Lepore.;Jose L Lopez-Sendon.;Ton Oude Ophuis.;Alexandr Parkhomenko.;Jennifer B Shannon.;Jindrich Spinar.;Jean-Francois Tanguay.;Mikhail Ruda.;P Gabriel Steg.;Pierre Theroux.;Stephen D Wiviott.;Ian Laws.;Marc S Sabatine.;David A Morrow.; .
来源: JAMA. 2016年315卷15期1591-9页
p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes.
1123. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
作者: Steven E Nissen.;Erik Stroes.;Ricardo E Dent-Acosta.;Robert S Rosenson.;Sam J Lehman.;Naveed Sattar.;David Preiss.;Eric Bruckert.;Richard Ceška.;Norman Lepor.;Christie M Ballantyne.;Ioanna Gouni-Berthold.;Mary Elliott.;Danielle M Brennan.;Scott M Wasserman.;Ransi Somaratne.;Rob Scott.;Evan A Stein.; .
来源: JAMA. 2016年315卷15期1580-90页
Muscle-related statin intolerance is reported by 5% to 20% of patients.
1127. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention.
作者: Robert W Yeh.;Eric A Secemsky.;Dean J Kereiakes.;Sharon-Lise T Normand.;Anthony H Gershlick.;David J Cohen.;John A Spertus.;Philippe Gabriel Steg.;Donald E Cutlip.;Michael J Rinaldi.;Edoardo Camenzind.;William Wijns.;Patricia K Apruzzese.;Yang Song.;Joseph M Massaro.;Laura Mauri.; .
来源: JAMA. 2016年315卷16期1735-49页
Dual antiplatelet therapy after percutaneous coronary intervention (PCI) reduces ischemia but increases bleeding.
|